UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

Date of Report: September 24, 2026

 

Commission File Number: 001-39307

 

 

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

 

On September 24, 2026, Legend Biotech Corporation (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Meeting”). The voting results are attached hereto as Exhibit 99.1.

 

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625 and 333-278050) and Form S-8 (Nos. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

 

 

EXHIBITS

  

Exhibit 99.1 — Voting Results of Annual General Meeting

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	LEGEND BIOTECH CORPORATION
Date: September 24, 2026	By:	/s/ Ingrid Zhang
	Name:	Ingrid Zhang
	Title:	Chief Executive Officer

 

 

Exhibit 99.1

 

Voting Results of 2026 Annual General Meeting

 

At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on September 24, 2026 (the “AGM”), the Company’s shareholders:

·

received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2025;

·

ratified the appointment of Ernst & Young LLP as the Company’s independent auditor for the fiscal year ending December 31, 2026;

·

re-elected each of Mr. Robin Meng, Dr. Corazon D. Sanders, Dr. Li Mao and Dr. Peter Salovey to serve as a Class III director for a three-year term;

·

approved the amendment and restatement of the Company’s 2020 Restricted Shares Plan to increase the aggregate number of ordinary shares reserved for issuance by 19,100,000 ordinary shares; and

·

authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

 

A total of approximately 330,199,682 ordinary shares, including those underlying ADSs, representing approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

 

		For								Against								Abstain
Resolutions		Votes				%				Votes				%				Votes				%
Reception of Audited Financial Statements			329,998,122				84.837	%			110,480				0.028	%			91,080				0.023	%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2026			329,955,758				84.827	%			144,190				0.037	%			99,734				0.026	%
Election of Directors
Mr. Robin Meng (Class III)			273,381,862				70.282	%			56,768,390				14.594	%			49,430				0.013	%
Dr. Corazon D. Sanders (Class III)			326,472,036				83.931	%			3,681,710				0.947	%			45,936				0.012	%
Dr. Li Mao (Class III)			328,120,942				84.355	%			1,999,436				0.514	%			79,304				0.020	%
Dr. Peter Salovey (Class III)			328,187,592				84.372	%			1,967,750				0.506	%			44,340				0.011	%
Amendment and Restatement of 2020 Restricted Shares Plan			279,130,008				71.760	%			20,732,988				5.330	%			30,336,686				7.799	%
Authorization of Directors and Officers			328,624,268				84.484	%			1,441,908				0.371	%			133,506				0.034	%